Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen

Medicine & Life Sciences

1. venetoclax 100%
2. Decitabine 85%
3. Acute Myeloid Leukemia 40%
4. GATA2 Deficiency 31%
5. Apoptosis 29%
6. Leukemia 20%
7. Stem Cells 18%
8. Survival 16%
9. Karyotype 16%
10. Mutation 16%
11. Cytogenetics 16%
12. Azacitidine 11%
13. Exome 9%
14. Apoptosis Regulatory Proteins 9%
15. Mutation Rate 8%
16. Appointments and Schedules 6%
17. Clone Cells 6%
18. Statistics 6%
19. Survival Rate 6%
20. Proteins 6%
21. Bone Marrow 6%
22. Elderly 5%
23. Biomarkers 5%